ASX-Dividend-Report-Banner
Sponsored

Radiopharm (ASX: RAD) expands isotope supply agreement with TerThera

August 24, 2023 01:30 PM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Radiopharm (ASX: RAD) expands isotope supply agreement with TerThera
Image source: Company website

Highlights

  • Radiopharm has expanded a supply agreement with TerThera for Tb-161 isotope.
  • The isotope will be linked to mAb to form RAD 402, a potential next-gen radiopharmaceutical being developed to treat advanced prostate cancer,
  • During the second half of 2024, RAD plans to begin RAD 402 Phase I trial to examine its safety and efficacy.

Radiopharm Theranostics Limited (ASX: RAD) has expanded its supply agreement with TerThera for Terbium-161 (Tb-161).

Aimed at forming RAD 402, the isotope will be linked to a proprietary monoclonal antibody (mAb).

RAD 402 is a radiotherapeutic being developed to target KLK3 expression. KLK3 has limited expression in healthy tissue but has high expression in prostate cancer cells.

The company intends to begin a phase I dose escalating trial in 2H24. The study would focus engage advanced prostate cancer patients to assess the efficacy and safety of radiotherapeutic. RAD would own the data generated, as well as discoveries and inventions made from the clinical trial. The three-year deal can be extended for another two years and will be effective from 28 August 2023. During 4Q23, the initial order with TerThera is anticipated.

RAD shares jump 5.6%

Following the update, RAD share price jumped by 5.68% to trade at AU$0.093 apiece at the time of writing early morning 24 August 2023.

More about Tb-161

Tb-161 is an isotope designed for targeted cancer treatment. The isotope is highly promising because of its unique properties of radiation emitted, which comprises both short-range beta particles and Auger electrons.  

RAD suggests that Tb-161 is potentially better than Lutetium-177 (Lu-177) as the Auger effect increases its efficacy and potency in destroying tumour cells selectively. Also, Tb-161 leaves surrounding healthy tissues largely unaffected.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.